Legal Representation
Attorney
David M. Perry
USPTO Deadlines
Next Deadline
46 days remaining
Abandonment Notice E-Mailed - No Use Statement Filed
Due Date
February 15, 2026
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 15, 2025 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Dec 15, 2025 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Oct 1, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 30, 2025 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| May 13, 2025 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Sep 30, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| May 14, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 13, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Nov 13, 2024 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Nov 13, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 8, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Nov 8, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Nov 8, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Nov 8, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Nov 8, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| May 14, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 13, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| May 13, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| May 13, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 16, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 14, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 14, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Nov 14, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 17, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 15, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 15, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 15, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 15, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 26, 2022 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Oct 21, 2022 | CHPB | I | POST PUBLICATION AMENDMENT - ENTERED | Loading... |
| Oct 11, 2022 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
| Sep 23, 2022 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
| Sep 20, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 20, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 31, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 17, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 17, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Aug 17, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 17, 2022 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 17, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 11, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 13, 2021 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Nov 12, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 5, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations, substances, active principles in the nature of therapeutic agents in the form of liquids, solutions, suspensions, injectables, eyedrops, tablets, powders, and capsules that provide the active ingredients for a wide variety of pharmaceuticals, and pharmaceutical compounds all for the treatment of inflammation, immune diseases and disorders, nervous system diseases and disorders, and ophthalmic diseases and disorders; ophthalmic preparations; oral medications in the nature of oral pharmaceuticals and therapeutics all for the treatment of ophthalmic diseases and disorders
Additional Information
Design Mark
The mark consists of the stylized wording "KIORA PHARMACEUTICALS"; to the left of the wording are lines running through a shaded circle with the lines resembling a stylized letter "K".
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMACEUTICALS"